Arbitrators Allow Exiqon to Sell LNA Products to Pharmaceutical Market | GenomeWeb

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Arbitrators have sided with Exiqon, allowing it to market locked nucleic acid-based LNA amidites and LNA oligonucleotides to the pharmaceutical market, the Danish firm announced today.

The decision by an arbitration court ends proceedings initiated by Exiqon last year against Santaris Pharma in a dispute over the LNA products.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PNAS this week: miR-515 levels higher in women with preeclampsia, horizontal gene transfer in parasitic plants, and more.

A cancer researcher retracts 19 articles from one journal for image manipulation, according to Retraction Watch.

Precision medicine has to consider context in addition to genetic mutations in cancer treatment, Medscape reports.

Genomics may help the Cavendish banana from succumbing to fungal infections, a trio of researchers writes at the Conversation.